Temozolomide , ≥98%(HPLC) , 85622-93-1
Synonym(s):
Temozolomide;3,4-Dihydro-3-methyl-4-oxoimidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide;3-Methyl-4-oxo-8-imidazolo[5,1-d][1,2,3,5]tetrazinecarboxamide;4-Methyl-5-oxo-2,3,4,6,8-pentazabicyclo[4.3.0]nona-2,7,9-triene-9-carboxamide;8-Carbamoyl-3-methylimidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one
CAS NO.:85622-93-1
Empirical Formula: C6H6N6O2
Molecular Weight: 194.15
MDL number: MFCD00866492
EINECS: 630-358-9
Pack Size | Price | Stock | Quantity |
250MG | RMB179.20 | In Stock |
|
500mg | RMB255.20 | In Stock |
|
1G | RMB401.60 | In Stock |
|
5G | RMB1077.60 | In Stock |
|
25g | RMB2736.00 | In Stock |
|
100g | RMB5471.20 | In Stock |
|
others | Enquire |
PRODUCT Properties
Melting point: | 212°C dec. |
Boiling point: | 526.6±42.0 °C(Predicted) |
Density | 1.97±0.1 g/cm3(Predicted) |
storage temp. | 2-8°C |
solubility | DMSO: soluble10mg/mL, clear |
pka | 14.77±0.20(Predicted) |
form | powder |
color | white to light brown |
Merck | 14,9139 |
Stability: | Stable for 2 years as supplied. Solutions in DMSO may be stored at -20° for up to 3 months. |
InChIKey | BPEGJWRSRHCHSN-UHFFFAOYSA-N |
Description and Uses
Temozolomide was launched for the first time in the UK for the
treatment of patients with glioblastoma multiforme showing recurrence or
progression after standard therapy. It can be considered as a cyclic variant of
highly reactive triazenes producing a cascade of ionic or radical antitumoral
species. Temozolamide is a 3-methyl analog of mitozolomide and was shown to
be converted to cytotoxic triazene MCTIC. It can be prepared in 2 steps from 5-
aminoimidazole-4-carboxamide by diazotization then cyclization with
methylisocyanate. Mechanistically, the depletion of O6-alkylguanine-DNA
alkyltransferase (OGAT) in cells or tumors was shown to be correlated with the
cytotoxicity of temozolomide which is a potent inhibitor of this enzyme involved
in DNA repair activity.
Further approval applications for the treatment of other malignant gliomas such
as relapsed anaplastic astrocytoma, advanced metastatic melanoma were
submitted.
Temozolomide is an antineoplastic drug and an Imidazotetrazine alkylating agent. It induces apoptosis and causes cell cycle arrest at the G2/M checkpoint. It rapidly degrades in the body, producing the active metabolite MTIC, which exerts an anti-tumor effect. Moreover, temozolomide has shown effectiveness against paclitaxel-resistant tumors and has been utilized in the study of drug resistance mechanisms in glioblastoma cell lines.
Safety
Symbol(GHS) | GHS07,GHS08 |
Signal word | Danger |
Hazard statements | H302-H315-H319-H335-H340-H350-H360FD |
Precautionary statements | P201-P202-P301+P312-P302+P352-P305+P351+P338-P308+P313 |
Hazard Codes | T,Xi |
Risk Statements | 45-46-60-61-22-36/37/38 |
Safety Statements | 24/25-45-36/37-26-53-36 |
WGK Germany | 3 |
RTECS | NJ5927050 |
HS Code | 29339900 |